Psalmotoxin 1 (C09-1164-111)

Psalmotoxin 1 (PcTx1) is a protein toxin that can bind at subunit-subunit interfaces of acid-sensing ion channel 1a (ASIC1a) . Psalmotoxin 1 is a potent and slective ASIC1a inhibitor (IC 50 : 0.9 nM) by increasing the apparent affinity for H + of ASIC1a. Psalmotoxin 1 can induce cell apoptosis , also inhibits cell migration, proferliration and invasion of cancer cells. Psalmotoxin 1 can be used in the research of cancers, or neurological diseaseIn VitroPsalmotoxin 1 (20 nM, 125 s) inhibits ASIC1a currents by drastically shifting the steady-state desensitization curve to lower H + concentrations. Psalmotoxin 1 (30 nM) competes with Ca 2+ in binding to ASIC1a channels. Psalmotoxin 1 (100 or 200 ng, 24-72 h) significantly weakens the migration, proliferation and invasion of MCF-7 and MDA-MB-231 cells . Psalmotoxin 1 (100 ng/mL, 24 h) significantly inhibits acid-induced increases in intracellular calcium and LDH release, induces cell apoptosis and cell cycle arrest in nucleus pulposus cells (NPCs) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation Assay Cell Line: MCF-7 and MDA-MB-231 cells Concentration: 100 or 200 ng Incubation Time: 24, 48, 72 h Result: Inhibited the cell migration, proliferation and invasion of breast cancer cells. Western Blot Analysis Cell Line: Nucleus pulposus cells (NPCs) Concentration: 100 ng/mL Incubation Time: 24 h Result: Decreased Bax and cleaved caspase-3 expression, and increased Bcl-2 expression.In VivoPsalmotoxin 1 (i.c.v., 1 ng/kg, a single dose) is neuroprotective in a conscious model of stroke via direct inhibition of ASIC1a. Psalmotoxin 1 (tail vein injection, 10 ng/kg, daily for 7 days) inhibits tumor growth in breast cancer mice model. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male spontaneously hypertensive rats (SHR)Dosage: 1 ng/kg, a single dose. Administration: Intracerebroventricular (i.c.v.) injection Result: Reduced cortical and striatal infarct volumes measured 72 h post-stroke. Reduced the severity of motor deficit at 1 and 3 days after stroke compared to control rats. Displayed an anti-apoptotic effect in the occluded hemisphere (reduced stroke-induced caspase-3 positive cells). Animal Model: Female nude BALB/C mice (orthotopic implantation, MCF-7 and MDA-MB-231 cells)Dosage: 10 ng/kg, daily for 7 days. Administration: Tail vein injection Result: Inhibited breast tumor growth.Form:SolidIC50& Target:IC50: 0.9 nM (ASIC1a), 50 nM (ASIC1b, ASIC2a, and ASIC3). Specifications and Purity: ≥99.0%. Molecular Formula: C200H312N62O57S6. Molecular Weight: 4689.41.